A Comparison of Two DAAs Used in a Unique Model of Care to Treat Hepatitis C Infections in New Jersey
In this prospective observational study, we compare the efficacy of glecaprevir/pibrentasvir vs sofosbuvir/velpatasvir in treating hepatitis C within a unique model of care utilizing a combination of telehealth, an ambulatory van, case management, and a contracted pharmacy. Among 769 patients treated, 90.4% completed treatment, with 9.6% lost to follow-up. Both regimens demonstrated high completion rates and efficacy.
Authors
- Paul Bellafiore
- Kevin Leyden
- Corey Rosmarin-DeStefano
- Barbara Tempalski (ORCID: https://orcid.org/0000-0002-6128-2510)
- Jihad Slim (ORCID: https://orcid.org/0000-0002-4192-7246)
- Sheena Duprey
- Emily Levaggi
- Juan Torres
Institutions
- North Jersey Community Research Initiative (US)
- Saint Michael's Medical Center (US)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2024-11-27
- DOI
- https://doi.org/10.1093/ofid/ofae645
- Citations
- 1
- Primary Topic
- Hepatitis C virus research
- Type
- article
- Field-Weighted Citation Impact
- 0.37